#PRESS #AscendisPharma is pleased to announce topline Week 78 data from COACH, our combination therapy trial in children with #achondroplasia. Learn more at investors.ascendispharma.com
AscendisPharma
@AscendisPharma
Ascendis Pharma is applying its innovative TransCon™ technology to build a leading biopharma company focused on making a difference in patients’ lives.
Joined March 2020
- #HCPs #ICYMI 2-year renal data from the #AscendisPharma Phase 3 PaTHway Trial of our treatment for #hypoparathyroidism in adults has been published in the Journal of Bone and Mineral Research (DOI: 10.1093/jbmr/zjag085).
- 📸 #HCPs The #AscendisPharma team had a great time at The Magic Foundation’s 32nd Annual Convention! We’re honored to support this inspiring community and share our commitment to advancing care for children with #growthhormonedeficiency #RareDisease
- #HCPs This week, #AscendisPharma is looking forward to attending The Magic Foundation’s 32nd Annual Convention dedicated to families of children affected by growth- and endocrine-related disorders. Visit our booth to learn more about our work in pediatric #growthhormonedeficiency
- This #ChronicDiseaseDay, #AscendisPharma is shining a light on the impact that chronic diseases have on the health and well-being of patients around the world, including rare endocrine diseases like #hypoparathyroidism and #growthhormonedeficiency. We're joining the global
